Reta GLP-1 & GIP

Retatrutide is an exciting new weight loss and diabetes drug. It is a triple-agonist, meaning that it activates three different hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon.

GLP-1 and GIP are hormones that are produced in the gut and help to regulate blood sugar levels. They do this by stimulating the release of insulin from the pancreas and by suppressing the release of glucagon from the liver. Insulin helps to lower blood sugar levels by allowing glucose to enter cells. Glucagon raises blood sugar levels by stimulating the liver to release glucose.

Retatrutide's triple-agonist effect means that it has a stronger effect on blood sugar control and weight loss than other diabetes or weight loss drugs that only target GLP-1 or GIP.

Retatrutide works to promote weight loss in several ways:

• It suppresses appetite. This is because GLP-1 and GIP both have an appetite-suppressing effect.
• It slows down digestion. This is because GLP-1 and GIP both slow down the movement of food through the digestive system. This makes you feel full for longer after eating.
• It increases energy expenditure. This is because GLP-1 and GIP both increase the body's metabolic rate. This means that you burn more calories at rest and during exercise.
• It reduces fat storage. This is because GLP-1 and GIP both promote the breakdown of fat cells.